Personalis Inc. (PSNL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Personalis Inc. (PSNL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.12

-0.23 (-4.30%)

At close: Jan 14, 2025, 3:59 PM

4.99

-2.44%

After-hours Jan 14, 2025, 06:30 PM EST

undefined% (undefined)

Bid	4.98
Market Cap	363.27M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.66
PE Ratio (ttm)	-3.08
Forward PE	n/a
Analyst	Strong Buy

Ask	5.75
Volume	634,314
Avg. Volume (20D)	983,119
Open	5.46
Previous Close	5.35
Day's Range	5.00 - 5.49
52-Week Range	1.12 - 7.20
Beta	undefined

About PSNL

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from ...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Jun 20, 2019

Employees 223

Stock Exchange NASDAQ

Ticker Symbol PSNL

Website https://www.personalis.com

Analyst Forecast

According to 4 analyst ratings, the average rating for PSNL stock is "Strong Buy." The 12-month stock price forecast is $8.12, which is an increase of 58.75% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Personalis Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $15.53M, reflecting a -21.07% YoY shrinking and earnings per share of -0.28, making a -48.15% decrease YoY.

Why Price Moved

3 weeks ago · Source

+9.32%

Personalis shares are trading higher after the com... Unlock content with Pro Subscription

3 weeks ago · Source

+47.75%

Moderna and Personalis shares are trading higher after signing a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157.

News

1 day ago · businesswire.com

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London's Francis Crick Institute and University College London,...

1 week ago · https://thefly.com

Personalis price target raised to $9 from $7 at Lake Street

Lake Street raised the firm's price target on Personalis to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm's estimate and consensus. W...

1 month ago · businesswire.com

Personalis to Participate at Upcoming Investor Conferences

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following inve...

2 months ago · seekingalpha.com

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

2 months ago · zacks.com

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.

2 months ago · businesswire.com

Personalis to Announce Third Quarter 2024 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday,...